US-based contract research organisation (CRO) Quintiles Transnational has hit a milestone with the start of its 400th clinical trial using electronic data capture (EDC) technology.
The company also said it had locked databases – the final step in electronic data capture – on more than 2700 EDC studies since 2000. To date, Quintiles has enrolled more than 400,000 patients at some 30,000 sites around the world using EDC.
The 400th trial is a Phase II study for AstraZeneca’s AZD7325, a GABA receptor subtype partial agonist under development for the treatment of anxiety.
According to Alex O’Toole, global head of ECD for Quintiles, the company’s “ability to scale up the use of EDC while maintaining great performance for our customers and our clinical investigators is unparalleled in the CRO marketplace”.
